» Articles » PMID: 19005480

Telomere Length is Severely and Similarly Reduced in JAK2V617F-positive and -negative Myeloproliferative Neoplasms

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2008 Nov 14
PMID 19005480
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by chronic proliferation of hematopoietic progenitors. We studied the telomere length (TL) of 335 MPN patients and 93 gender- and age-matched controls using a quantitative PCR method (relative TL calculated as the ratio of the amount of telomere DNA vs single-copy DNA: T/S ratio). TL was markedly reduced in MPN patients compared with controls (T/S 0.561 vs 0.990, P<0.001). In JAK2V617F MPN patients, TL correlated inversely with allelic burden (P<0.001). Patients homozygous for the mutation (allelic burden 90-100%) had the shortest TL, even when compared with patients with lower allele burdens consistent with a dominant heterozygous population (allelic burden 55-65%) (T/S 0.367 vs 0.497, P=0.037). This suggests that the high degree of proliferation of the MPN clone reduces TL and suggests the possibility that TL shortening may be indicative of progressive genomic instability during MPN progression. The TL of JAK2V617F-negative MPN patients was similar to JAK2V617F-positive counterparts (T/S 0.527 vs 0.507, P=0.603), suggesting that the yet-to-be-discovered causative mutation(s) impact the mutated stem cell similarly to JAK2V617F, and that TL measurement may prove useful in the diagnostic workup of JAK2V617F-negative MPN.

Citing Articles

Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database.

Yan J, Hammami M, Wei J, Shah N, Goldfinger M, Mantzaris I Ann Hematol. 2024; 103(9):3543-3551.

PMID: 39046510 PMC: 11358356. DOI: 10.1007/s00277-024-05894-7.


Telomerase-targeted therapies in myeloid malignancies.

Waksal J, Bruedigam C, Komrokji R, Jamieson C, Mascarenhas J Blood Adv. 2023; 7(16):4302-4314.

PMID: 37216228 PMC: 10424149. DOI: 10.1182/bloodadvances.2023009903.


Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.

Nakao T, Bick A, Taub M, Zekavat S, Uddin M, Niroula A Sci Adv. 2022; 8(14):eabl6579.

PMID: 35385311 PMC: 8986098. DOI: 10.1126/sciadv.abl6579.


Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.

Giaccherini M, Macauda A, Sgherza N, Sainz J, Gemignani F, Maldonado J Blood Cancer J. 2020; 10(8):89.

PMID: 32873778 PMC: 7463014. DOI: 10.1038/s41408-020-00356-5.


Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A Blood Cancer J. 2018; 8(10):89.

PMID: 30291232 PMC: 6173714. DOI: 10.1038/s41408-018-0128-x.


References
1.
Greider C . Telomere length regulation. Annu Rev Biochem. 1996; 65:337-65. DOI: 10.1146/annurev.bi.65.070196.002005. View

2.
Vogelstein B, Fearon E, Hamilton S, Preisinger A, Willard H, MICHELSON A . Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res. 1987; 47(18):4806-13. View

3.
DUNHAM M, Neumann A, Fasching C, Reddel R . Telomere maintenance by recombination in human cells. Nat Genet. 2000; 26(4):447-50. DOI: 10.1038/82586. View

4.
Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

5.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo S, Lippert E . Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007; 110(1):375-9. DOI: 10.1182/blood-2006-12-062125. View